Skip to main content
Clinical Trials/NCT01742195
NCT01742195
Completed
Not Applicable

Randomized Study Comparing the Oral and Nasal Routes for Linear Endobronchial Ultrasound

Laval University1 site in 1 country220 target enrollmentNovember 2012
ConditionsSatisfaction

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Satisfaction
Sponsor
Laval University
Enrollment
220
Locations
1
Primary Endpoint
Patient comfort and satisfaction
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

The aim of this study is to determine if the insertion of the linear endobronchial ultrasound bronchoscope is more comfortable for patients when done through the nose compared to its insertion through the mouth. Our hypothesis is that nasal insertion is more comfortable.

Detailed Description

Linear endobronchial ultrasound (EBUS) now plays a crucial role in the diagnosis, staging, and treatment planning of lung cancer. Most centers perform linear EBUS via the oral route given the larger diameter of the bronchoscope used. However, the feasibility and the diagnostic accuracy of linear EBUS performed through the nose have not been reported. Furthermore, the two routes of insertion have never been compared in terms of patient satisfaction and comfort. In order to compare the two routes of insertion, consecutive patients referred for a linear endobronchial ultrasound will be recruited. Participants will be randomized to either oral or nasal insertion. All participants will be sedated and will receive local anesthetics in a similar manner. After the procedure, patients will fill a questionnaire regarding their comfort and satisfaction with the procedure.

Registry
clinicaltrials.gov
Start Date
November 2012
End Date
June 2013
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Antoine Delage

MD

Laval University

Eligibility Criteria

Inclusion Criteria

  • patients older than 18 years of age
  • patients referred for a first linear endobronchial ultrasound

Exclusion Criteria

  • Patients who previously underwent an EBUS
  • Patients intubated with an endotracheal tube
  • Patients under the age of 18
  • Patients unable to provide informed consent
  • Patients currently taking anticoagulants (therapeutic doses of intravenous or subcutaneous heparin, low-molecular weight heparins, direct thrombin inhibitors or other agents)
  • Patients taking anti-platelet therapy other than aspirin (clopidogrel, ticagrelor, prasugrel). A period of 7 days off medication is required before participation.

Outcomes

Primary Outcomes

Patient comfort and satisfaction

Time Frame: Two hours after endobronchial ultrasound

Measured by a questionnaire using a 10-point Likert scale for both comfort and satisfaction.

Secondary Outcomes

  • Physician's assessment of patient comfort(Immediately after the procedure (within 10 minutes))
  • Duration of endobronchial ultrasound procedure(During the procedure)
  • Total doses of sedation(Immediately after the procedure (within 10 minutes))
  • Occurence of pneumothorax, bleeding more than 50ml, oxygen desaturation to less than 90%, epistaxis, cardiac arrhythmia(During the procedure and up to two hours after)
  • Proportion of adequate cytology specimens in each group(Days after the procedure (results usually available within 10 days))

Study Sites (1)

Loading locations...

Similar Trials